Astro Pak launches decontamination services subsidiary

Published: 26-Jan-2010
Hi Tech Manufacturing Finance Cleaning

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.

The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.

The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.

Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.

In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
  • Companies:
  • Instant Cleanroom Solutions
See more

You may also like

Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Read more
Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines

Trending Articles

  1. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  2. T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both technologies in-house
  3. Eli Lilly to expand into infectious disease with $4bn triple vaccine acquisition The pharma giant has reportedly agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co in a strategic push beyond its blockbuster obesity franchise
  4. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  5. Almac group delivers record year of growth Revenue rises to £1.1 billion as profit increases 16% and workforce expands to more than 7,900 amid continued global investment programme

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Finance

Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA

SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
Manufacturing

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
Finance

T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline

Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both technologies in-house
Manufacturing

CordenPharma acquires AmbioPharm to build three-continent peptide API network

The deal adds US and Shanghai manufacturing sites to CordenPharma's existing platform, giving pharma customers greater flexibility across SPPS, LPPS and hybrid peptide synthesis at commercial scale
Manufacturing

Almac group delivers record year of growth

Revenue rises to £1.1 billion as profit increases 16% and workforce expands to more than 7,900 amid continued global investment programme
Subscribe now